Bioengineering Synthetic Elastin Conduits For Arterial Revascularisation
Funder
National Health and Medical Research Council
Funding Amount
$624,776.00
Summary
An arterial substitute with both physical and biological properties that mimic those of the human vasculature has long been the holy grail of vascular tissue engineering. We propose synthetic elastin can form the basis of a durable, clinically effective small diameter vascular graft and fill a significant unmet need for a biocompatible vascular substitute.
Biocompatible Synthetic Conduits To Treat Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$421,818.00
Summary
Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular diseas ....Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular disease.Read moreRead less
Bioengineering Endovascular Prostheses With Proactive Biocompatibility
Funder
National Health and Medical Research Council
Funding Amount
$627,950.00
Summary
Metallic cardiovascular implants, such as stents, used in the treatment of heart disease are not compatible with blood. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of metal alloys, and shown a significant improvement in their compatibility. Stents coated using our technology stand to dramatically improve the treatment of cardiovascular disease.
Development Of Endovascular Stents With Proactive Biocompatibility
Funder
National Health and Medical Research Council
Funding Amount
$428,470.00
Summary
Metallic cardiovascular implants, such as stents, used in the treatment of heart disease are not compatible with blood. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of metal alloys, and shown a significant improvement in their compatibility. Stents coated using our technology stand to dramatically improve the treatment of cardiovascular disease.
New Materials for an Implantable Blood Pump. Rotary blood pumps are at the leading edge of heart assist technology. VentrAssist has developed an innovative rotary blood pump with a hydro-dynamically suspended impeller. Advanced surface modifications will enable the device to be fabricated from polymers; this will make the device light, more compatible with the human body and less costly to produce. Surface treatments and coatings will be applied using ion implantation, to impart the required ....New Materials for an Implantable Blood Pump. Rotary blood pumps are at the leading edge of heart assist technology. VentrAssist has developed an innovative rotary blood pump with a hydro-dynamically suspended impeller. Advanced surface modifications will enable the device to be fabricated from polymers; this will make the device light, more compatible with the human body and less costly to produce. Surface treatments and coatings will be applied using ion implantation, to impart the required dimensional stability, impermeability and wear resistance. Following sophisticated experiments of modified materials, the best candidates will be used in prototype devices, for final selection of the optimal materials for the new device.Read moreRead less
Hydrogel systems for effective encapsulation of functional pancreatic islet cells. This proposal addresses the problem of maintaining viability and function of cells encapsulated within an immuno-isolation barrier material. The research will develop biosynthetic materials that are able to meet design criteria for an effective biomaterial for this application. The major benefits to Australia will be in improved health outcomes by providing safer, more efficacious materials, economic growth develo ....Hydrogel systems for effective encapsulation of functional pancreatic islet cells. This proposal addresses the problem of maintaining viability and function of cells encapsulated within an immuno-isolation barrier material. The research will develop biosynthetic materials that are able to meet design criteria for an effective biomaterial for this application. The major benefits to Australia will be in improved health outcomes by providing safer, more efficacious materials, economic growth development of the Australian Medical Device industry and in high level training of researchers in this field.Read moreRead less
The Scale-up and Evaluation of a Novel Dense Gas Technology Platform for the Production of Particles for Aerosol Drug Delivery. This project provides a unique opportunity to develop an Australian-invented technology in particle engineering, enabling it to enter the international pharmaceutical market. This will enhance the growth of Australia's pharmaceutical research and development, and benefit the Australian pharmaceutical industry. The outcome will also contribute to improvements in the heal ....The Scale-up and Evaluation of a Novel Dense Gas Technology Platform for the Production of Particles for Aerosol Drug Delivery. This project provides a unique opportunity to develop an Australian-invented technology in particle engineering, enabling it to enter the international pharmaceutical market. This will enhance the growth of Australia's pharmaceutical research and development, and benefit the Australian pharmaceutical industry. The outcome will also contribute to improvements in the health and well-being of Australians. The research falls within the Designated National Research Priority of Frontier Technologies for Building and Transforming Australian Industries.Read moreRead less
Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasm ....Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasma, which is the current agent used to treat patients with AAT-misfolding disease.Read moreRead less
Functional drug-releasing polymer nano-composites for preventing medical device infection and encrustation. By developing new methodologies for producing functional biomaterials, this research will benefit Australia by continuing our high profile in this research field and by producing economic benefits arising from development and export of materials technologies to the major user groups in USA and Europe. With our demonstrated linkages with Australian based biomaterials developers at CSIRO an ....Functional drug-releasing polymer nano-composites for preventing medical device infection and encrustation. By developing new methodologies for producing functional biomaterials, this research will benefit Australia by continuing our high profile in this research field and by producing economic benefits arising from development and export of materials technologies to the major user groups in USA and Europe. With our demonstrated linkages with Australian based biomaterials developers at CSIRO and University of Queensland, as well as with companies involved in the commercialisation of polyurethane based medical devices (Aortech P/L), this group is well placed to continue the research at a more applied level once the early basic stage is complete.Read moreRead less